NDAORALTABLET
Approved
Nov 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
12
Mechanism of Action
Cytochrome P450 3A Inhibitors
Pharmacologic Class:
Cytochrome P450 3A Inhibitor
Clinical Trials (5)
Analysis of Crushed and Whole Tablet Genvoya
Started Apr 2019
12 enrolled
Healthy Volunteers
Same-Day Treatment With Genvoya vs. EFV/TDF/3TC
Started May 2018
0HIV/AIDS
Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy
Started Feb 2018
25 enrolled
HIV-1-infectionHepatitis C, ChronicMethadone Dependence+6 more
Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis
Started Mar 2017
101 enrolled
HIV Risk
An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal
Started Sep 2014
30 enrolled
HIV-2 Infection
Loss of Exclusivity
LOE Date
Apr 6, 2033
86 months away
Patent Expiry
Apr 6, 2033
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 7176220 | Aug 27, 2026 | SubstanceProduct | U-257 |
| 7635704 | Oct 26, 2026 | SubstanceProduct | U-257 |
| 8981103 | Oct 26, 2026 | SubstanceProduct | — |
| 7176220*PED | Feb 27, 2027 | — | |
| 8981103*PED | Apr 26, 2027 | — |